Cytopoint (10 - 20 kg)
Active substance
ATC code
Species
Dogs
Indications
Treatment of pruritus associated with allergic dermatitis in dogs.
Treatment of clinical manifestations of atopic dermatitis in dogs.
Dose to be administered and administration route
Subcutaneous use.
Avoid excessive shaking or foaming of the solution. Administer the entire contents (1 ml) of the vial.
Dose according to the dosing chart below. For dogs above 40 kg, the contents of more than one vial are required to administer a single dose. In those cases, withdraw the appropriate content from each required vial into the same syringe. To allow for mixing of the solution, gently invert the syringe three or four times before administering.
Dosage and treatment schedule:
The recommended minimum dose is 1 mg/kg bodyweight, once a month. The need for repeat or longer-term treatment in dogs with allergic dermatitis should be based on the needs of the individual patient including an assessment by the responsible veterinarian of the ability to avoid/eliminate the allergenic stimulus (see also section 4.5). Dose according to the dosing chart below:
|
CYTOPOINT strength (mg) and number of vials to be administered |
||||
|
Bodyweight (kg) of dog |
10 mg |
20 mg |
30 mg |
40 mg |
|
3.0-10.0 |
1 |
|||
|
10.1-20.0 |
1 |
|||
|
20.1-30.0 |
1 |
|||
|
30.1-40.0 |
1 |
|||
|
40.1-50.0 |
1 |
1 |
||
|
50.1-60.0 |
2 |
|||
|
60.1-70.0 |
1 |
1 |
||
|
70.1-80.0 |
2 |
|||
Adverse reactions
Hypersensitivity reactions (anaphylaxis, facial oedema, urticaria) have been reported to occur in rare cases from spontaneous reports. In such cases appropriate treatment should be administered immediately.
Vomiting and/or diarrhoea have been reported to occur in rare cases from spontaneous reports and may occur in connection with hypersensitivity reactions.
Treatment should be administered as needed.
Neurological signs (seizure, convulsion or ataxia) have been rarely observed in spontaneous reports following use of the veterinary medicinal product.
Application site disorders (injection site pain, injection site swelling) have been reported very rarely in spontaneous reports.
Clinical signs of immune-mediated diseases, such as haemolytic anaemia or thrombocytopenia, have been reported very rarely in spontaneous reports.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
